ClinicalTrials.gg
TerminatedNCT04517448EQLVCPALUpdated Sep 26, 2024

Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy

An observational study in Colorectal Cancer, Pancreatic Cancer and Biliary Cancer, sponsored by Centre Hospitalier de la côte Basque. Terminated at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Centre Hospitalier de la côte Basque · Observational

How we know

Why this study was terminated
End of recruitment - Number of required subjects enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
31
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Enrollment
91st of 103
31 · median 274
Started
2020
with 27 others
Observational
103 of 583
21 open now
Registered
390th of 583
by date

Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 91st largest by enrollment of the 103 observational ones that give a count, is one of 28 that started in 2020, is one of 103 observational ones, and was the 390th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 75 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 583 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

The aim of this research is to evaluate the quality of life of patients over 75 years of age undergoing palliative chemotherapy for digestive cancer. It is a non-interventional study that evaluates the quality of life before and after a cycle of chemotherapy with a composite criterion including: a standardized questionnaire "Cancer specific quality of Life questionnaire" (QLQC30), an assessment of autonomy by "Activity of daily living" questionnaire (ADL), and the number of days of hospitalization.

Read the detailed description

The number of patients undergoing chemotherapy continues to increase as well as the age of cancer patients, it is estimated that in 2050 one cancer out of two will be discovered in a person over 75 years of age. Digestive cancers account for the majority of these patients, the goals of these palliative chemotherapies are to improve survival and maintain or improve quality of life. Since the 2009 cancer plan, a specific geriatric onco-geriatrics organization has been set up with the creation of geriatric onco-coordination units. One of the objectives of this plan is to achieve a 5% inclusion rate of patients over 75 years of age in clinical trials. However, there are relatively few studies in patients over 75 years of age concerning quality of life, as they are often excluded from trials and survival is preferred as the primary outcome. This observational study evaluates the quality of life of patients at the time of the first chemotherapy treatment and then at the end of the first cycle of chemotherapy at 3 months by a standardized questionnaire, an evaluation of autonomy and the number of days of hospitalization.

03

Conditions studied

  • Colorectal Cancer
  • Pancreatic Cancer
  • Biliary Cancer
  • Hepatic Cancer
  • Oesophageal Cancer
  • Gastric Cancer

Keywords

  • Digestive cancer, age other 75 years old, palliative therapy, quality of life
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patient other 75 years old, undergoing a palliative chemotherapy for a digestive cancer : colorectal, pancreatic, biliary, oesophageal, gastric, proved by histology, whatever the histologic type (adenocarcinoma, epidermoid carcinoma, neuroendocrine carcinoma); at a palliative stage (not resecable, multimetastatic) and who will perform a first course of palliative chemotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 75 years old
  • Suffering from digestive cancer : colorectal, pancreatic, biliary, oesophageal, gastric
  • Palliative cancer : not resectable, multimetastatic
  • Decision in multi-disciplinary liaising meeting (CPR) to perform a first course of palliative chemotherapy
  • Having received an form
  • Understanding french language

Exclusion criteria

Exclusion Criteria:

  • Cognitive disorders
  • Patient benefiting from a legal protection measure
  • below 1 year
  • Not understanding french language
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
31 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in the response scores to the standardized questionnaire Quality of life questionnaire in cancer patient

    The primary outcome is a composite criterion comparing the response scores to the standardized questionnaire Quality of life in cancer patient . These data will be collected during the first inpatient chemotherapy course in hospitalization and during the last chemotherapy before evaluation. A higher score would mean a worsening of the situation

    Time frame: Before first chemotherapy and at Month 3 of chemotherapy

Secondary outcomes

  1. Change in the Activity of daily living score

    The secondary outcome in to compare the Activity of daily living score at first chemotherapy and at the end of the first cycle at 3 months. We will collect the patient's place of residence in order to look for possible institutionalization, which is an important marker of quality of life. A higher score would mean a worsening of the situation.

    Time frame: Before first chemotherapy and at Month 3 of chemotherapy

07

Study locations

1 site
  • CH Côte Basque
    Bayonne, 64109, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Oct 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 18, 2020
StartActual
Oct 16, 2020
Primary completionActual
Oct 23, 2021
CompletionActual
Nov 23, 2021
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04517448
Lead sponsor
Centre Hospitalier de la côte Basque
Responsible party
AUDEMAR Franck (Principal investigator, Centre Hospitalier de la côte Basque) — Principal investigator
First posted
Aug 18, 2020
Start date
Oct 16, 2020
Primary completion
Oct 23, 2021
Completion
Nov 23, 2021
Last update
Sep 26, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion